To combat this, initial strategies to develop incretin based “replacement” therapies largely focused on GLP-1 receptor analogs because studies suggested diabetic patients are resistant to GIP treatment [34, 35], while GLP-1 infusion elicits a strong insulin secretory response and can normalize hyperglycemia [36–39]. The gene discussed is GLP1R; the disease is Hyperglycemia.